Beanne warning letter could be sign of greater foreign focus by FDA

01/31/2013 | In-PharmaTechnologist.com

The FDA issued a warning letter to Beanne Chemical for what the agency said were violations of current good manufacturing practices, including failure to correctly validate manufacturing procedures, maintain laboratory raw data and perform in-process testing. The second cGMP warning this year for a foreign manufacturer could be a sign of more to come from the FDA, according to this article.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC